What the business is, and whether it's a good one at a fair price.
Makes and sells Ayurvedic and herbal healthcare products in two streams — human healthcare (45% of revenue) and veterinary/animal healthcare (55%) — across a portfolio of roughly 300 formulations from a manufacturing facility in Himatnagar, Gujarat. Revenue of ₹73.13 Cr in FY26 came from distribution across more than 15 Indian states and from exports to 8 countries including UAE, Kuwait, Iraq, Qatar, Nepal, Bangladesh, Mauritius, Yemen and Sudan, with export revenue at ₹6 Cr (up 164% YoY). Distribution is being expanded through government procurement channels (state schemes, CSD, CGHS, KPKB) and a sales team that the company targets to double from about 80 people in the next two years. Materials (raw herbs, packaging and formulations inputs) are the dominant cost, eating 76% of revenue, with employee cost at 2.5% and other operating expenses at 4.1%. A second manufacturing facility near Ahmedabad (capex of ₹12-15 Cr, land already acquired for ₹2.5 Cr) is set to start installations from CY2027, and management has guided to an FY30 revenue target of ₹200 Cr.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from SHELTER PHARMA LIMITED's filed financials and exchange disclosures
SHELTER PHARMA LIMITED is a Pharmaceuticals & Biotechnology company listed on BSE.
Yes. The dividend yield is 0.74% at the current price.
Effectively yes. It holds ₹1 Cr more cash than debt.
On trailing P/E, SHELTER PHARMA LIMITED ranks 4 of 169 in Pharmaceuticals — cheaper than 98% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session SHELTER PHARMA LIMITED moves 2.02% — that is the median absolute close-to-close move across its last 246 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by SHELTER PHARMA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
